



31 January 2025

Quarterly Activities and Cash Flow Report

Quarter ended 31 December 2024

Key highlights

- In Q2 FY25, dorsaVi achieved sales revenue of \$330k (increase of 1.9% to Q1 FY25: \$324k)
- During the quarter, dorsaVi received cash receipts of \$329k and had net operating cash inflow of \$86k (including government grants)
- dorsaVi performed a commercial release of the advanced AI powered movement analysis platform, Video AI module, that has been in *beta* testing at 15 US sites
- Mr Leigh Travers was appointed to the Board as a Non-Executive Director and brings to dorsaVi over a decade of experience in building products and growing networks in the digital asset and technology industries
- dorsaVi formed a collaborative partnership with Secret Network, testing the integration of privacy-preserving blockchain technology with dorsaVi's device and Video AI data
- dorsaVi holds cash balance of \$1.24 million at 31 December 2024, which included receipt of the FY24 R&D Tax rebate of ~\$415k

Melbourne, Australia, 31 January 2025: dorsaVi (ASX:DVL) (**dorsaVi** or the **Company**) today released its Quarterly Activities Report and Quarterly Cashflow Report (Appendix 4C) for the quarter ended 31 December 2024.

Financial update

In Q2 FY25, dorsaVi recorded cash receipts from customers of \$329k during the quarter (Q1 FY25: \$398k) and cash expenses of \$665k, (Q1 FY25: 756k). As a result, dorsaVi recorded Q2 FY25 net operating cash inflows (including government grants of \$415k) of \$86k.

dorsaVi recognised sales revenue of \$330k, representing an increase of 1.9% compared to the previous quarter (Q1 FY25: \$324k).

Commercial Release of AI-Powered Video Movement Analysis Platform

During the quarter, dorsaVi launched its Video AI platform and has seen immediate interest and uptake from professional sporting teams and US physical therapy clinics. The Video AI platform represents a significant milestone in dorsaVi's product evolution and expands the Company's suite of non-intrusive, high-precision movement tracking solutions by utilising video capture from a range of devices to deliver advanced movement analysis. The platform complements dorsaVi's core sensor technology used by leading organisations worldwide, offering enhanced scalability, cost efficiency, and the ability to analyse natural movement patterns within seconds.

The Video AI application reduces set up time by 90%, allowing clinicians to communicate more efficiently with their patients and create more revenue for their clinic. From dorsaVi's perspective, the Video AI product has significantly higher margins (>70%) than our sensor-based products, as there are no sensors required, no shipping and less time to train clinicians. Customers can simply pay through the website, download the app and be assessing patients within minutes.

Video AI introduces three specialised modules—upper limb, lower limb, and running—each tailored to address unique movement analysis needs. These modules are designed to provide clinicians, sports performance experts, and researchers with accurate, real-time data to support personalised treatment plans and optimise performance. By addressing high-demand areas in clinical and sports settings, Video AI can help create new revenue opportunities for our target customers.

Blockchain Integration

During the quarter, the Company announced that it had commenced a strategic feasibility study to incorporate blockchain technology into its core data platform. This carefully designed initiative reflects the company's commitment to addressing the growing data security and privacy requirements of its largest enterprise clients already working with the sensitive health and biomechanical data generated by dorsaVi's best-in-class wearable devices and software.

The evaluation will focus on how blockchain technology could be integrated into its existing data architecture to enhance data integrity, storage security, and privacy controls for the Company's current enterprise-grade healthcare and workplace applications. The initiative directly complements dorsaVi's existing capabilities, including its AI-driven video-based tracking tool ViMove+, and is a response to the growing demands of the Company's enterprise clients. The scoping phase is expected to deliver an integration roadmap.

The Role of Blockchain in Healthcare Data Security

Blockchain technologies offer unique advantages for managing sensitive health and biomechanical data. Its decentralised, immutable architecture could provide a tamper-proof framework for data storage and sharing, reducing vulnerabilities associated with centralised systems. dorsaVi's technical review has a specific focus on leveraging advanced consensus mechanisms like Proof-of-Stake (PoS) and Directed Acyclic Graphs (DAGs), which offer energy-efficient scalability and security, tailored to the needs of mobile health data applications.

Secret Network Partnership

During the quarter the Company announced a new partnership with Secret Network, a leader in privacy-preserving blockchain technologies.

The partnership will explore and test (in a sandbox environment) the technical feasibility of integrating dorsaVi's proprietary devices with Secret Network's encrypted smart contract technology to secure user movement data collected for injury prevention, rehabilitation, and performance enhancement. The collaboration will assess the use of various data tokenization methods, including issuing Non-Fungible Tokens (NFTs) which represent ownership and secure access to confidential data.

As part of the partnership, Secret Network will provide software development resources at no cost to dorsaVi to complete the proof of concept. Any technical knowledge and commercial interest generated beyond the proof of concept is expected to guide decisions on the future nature of the partnership.

Corporate update

During the quarter, Mr Leigh Travers was appointed to the Board as a Non-Executive Director on 4 December 2024. Mr Travers is an experienced executive who has spent over a decade building products and growing networks in the digital asset and technology industries.

Mr Travers is currently the Director of Emerging Markets with Hong Kong-based web3 investment and incubation company Animoca Brands. Animoca Brands is one of the most active investors in web3 and recently launched the Mocaverse, a platform that enables consumers to maximize their Web3 exposure to experiences and rewards and trading at over A\$1B on a fully diluted basis. Mr Travers is responsible for investments and partnerships as well as providing insights and recommendations to the leadership team on regulatory and compliance matters.

Mr Travers was previously the CEO of Binance Australia from 2021 to mid-2023, leading one of the region's largest and fastest growing fintechs from 500k to 1m customers with trading volumes consistently over several billion dollars per week.

Mr Travers has also been a Director and CEO of DigitalX Limited (ASX:DCC), the world's first publicly listed blockchain technology company and served on the Board of Australia's blockchain industry body, Blockchain Australia for five years. During Mr Travers' time as CEO of DigitalX, he oversaw significant growth in the company's assets from \$100,000 in late 2016 to over \$50 million in 2021¹.

He has spent his career in public markets, including as a Non-Executive Director for investment and technology companies on the NASDAQ and the TSX

On 15 November 2024, the Company issued 50,000,000 New Shares with an issue price of \$0.011 (1.1 cents) per Share completing the \$1.1m capital raising which was announced in the September 2024 quarter. The proceeds raised will be used to accelerate the commercialisation of AI enhanced products in the US, expand AI features and solutions, and for general working capital.

As at 31 December 2024, dorsaVi held a cash balance of \$1.24 million.

Payments related to Item 6.1 of Appendix 4C relate to the Chief Executive Officer's salary and Directors fees for the quarter.

This release has been authorised for lodgement to the ASX by the Board.

- ENDS -

¹ <https://coinmarketcap.com/currencies/mocaverse/nts/bitcoin-and-digital-asset-exposure-august-2021-6A1049156>

For further information about dorsaVi, please contact:

Company

Andrew Ronchi

Chief Executive Officer

+61 417 882 267

Email: ar@dorsavi.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com

3Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

dorsaVi Ltd

ABN

15 129 742 409

Quarter ended ("current quarter")

December 2024

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	329	727
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(11)	(60)
(c) advertising and marketing	(17)	(40)
(d) leased assets	(14)	(25)
(e) staff costs	(260)	(537)
(f) administration and corporate costs	(359)	(755)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	7	10
1.5 Interest and other costs of finance paid	(4)	(7)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	415	415
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	86	(272)

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
	(d) investments	-	-
	(e) intellectual property	(9)	(11)
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(9)	(11)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	545	1,095
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(33)	(66)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	512	1,029

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	629	478
4.2	Net cash from / (used in) operating activities (item 1.9 above)	86	(272)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(9)	(11)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	512	1,029
4.5	Effect of movement in exchange rates on cash held	23	17
4.6	Cash and cash equivalents at end of period	1,241	1,241

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,157	547
5.2	Call deposits	84	82
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,241	629

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	52
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<p><i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i></p> <p>Payments to related parties and their associates included at 6.1 include:</p> <ul style="list-style-type: none"> - Salary and superannuation to CEO (director of the entity) - \$39K - Director Fees Paid - \$13K 		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Unsecured loan facility	-	-
7.2	Credit standby arrangements	-	-
7.3	Secured loan facility	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	N/A		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	86
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,241
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	1,241
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	14.43
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 January 2025

Authorised by: By the Board of Directors

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.